Your browser doesn't support javascript.
loading
Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.
Micol, Jean-Baptiste; Duployez, Nicolas; Boissel, Nicolas; Petit, Arnaud; Geffroy, Sandrine; Nibourel, Olivier; Lacombe, Catherine; Lapillonne, Helene; Etancelin, Pascaline; Figeac, Martin; Renneville, Aline; Castaigne, Sylvie; Leverger, Guy; Ifrah, Norbert; Dombret, Hervé; Preudhomme, Claude; Abdel-Wahab, Omar; Jourdan, Eric.
Afiliación
  • Micol JB; Hematology Department, INSERM Unité Mixte de Recherche 1009, Gustave Roussy Cancer Campus Grand Paris, Villejuif, Paris-Sud University, Orsay, France; Human Oncology and Pathogenesis Program and Leukemia Service, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY;
  • Duployez N; Laboratory of Hematology and Tumor Bank, INSERM U837 Team 3, Cancer Research Institute of Lille, Centre Hospitalier Régional Universitaire of Lille, University Lille Nord de France, Lille, France;
  • Boissel N; Department of Hematology and EA3518, Hôpital Saint-Louis (Assistance Publique-Hôpitaux de Paris), University Paris Diderot, Paris, France;
  • Petit A; Department of Pediatric Hematology, Hôpital Armand Trousseau (Assistance Publique-Hôpitaux de Paris), Paris, France;
  • Geffroy S; Laboratory of Hematology and Tumor Bank, INSERM U837 Team 3, Cancer Research Institute of Lille, Centre Hospitalier Régional Universitaire of Lille, University Lille Nord de France, Lille, France;
  • Nibourel O; Laboratory of Hematology and Tumor Bank, INSERM U837 Team 3, Cancer Research Institute of Lille, Centre Hospitalier Régional Universitaire of Lille, University Lille Nord de France, Lille, France;
  • Lacombe C; Laboratory of Hematology and Tumor Bank, Hôpital Cochin (Assistance Publique-Hôpitaux de Paris), Paris, France;
  • Lapillonne H; Laboratory of Hematology, Hôpital Armand Trousseau (Assistance Publique-Hôpitaux de Paris), Groupe Hospitalier Universitaire de l'Est Parisien, Paris, France;
  • Etancelin P; Laboratory of Hematology and Tumor Bank, INSERM U837 Team 3, Cancer Research Institute of Lille, Centre Hospitalier Régional Universitaire of Lille, University Lille Nord de France, Lille, France;
  • Figeac M; Functional and Structural Genomic Platform, Lille 2 University, IFR-114, Lille, France;
  • Renneville A; Laboratory of Hematology and Tumor Bank, INSERM U837 Team 3, Cancer Research Institute of Lille, Centre Hospitalier Régional Universitaire of Lille, University Lille Nord de France, Lille, France;
  • Castaigne S; Department of Hematology, Versailles Hospital, Le Chesnay, France;
  • Leverger G; Department of Pediatric Hematology, Hôpital Armand Trousseau (Assistance Publique-Hôpitaux de Paris), Paris, France;
  • Ifrah N; Department of Hematology, INSERM U892, Centre Hospitalier Universitaire d'Angers, Angers, France; and.
  • Dombret H; Department of Hematology and EA3518, Hôpital Saint-Louis (Assistance Publique-Hôpitaux de Paris), University Paris Diderot, Paris, France;
  • Preudhomme C; Laboratory of Hematology and Tumor Bank, INSERM U837 Team 3, Cancer Research Institute of Lille, Centre Hospitalier Régional Universitaire of Lille, University Lille Nord de France, Lille, France;
  • Abdel-Wahab O; Human Oncology and Pathogenesis Program and Leukemia Service, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY;
  • Jourdan E; Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nimes, University Montpellier-Nimes, Nimes, France.
Blood ; 124(9): 1445-9, 2014 Aug 28.
Article en En | MEDLINE | ID: mdl-24973361
ABSTRACT
Acute myeloid leukemia (AML) with t(8;21) (q22;q22) is considered to have favorable risk; however, nearly half of t(8;21) patients are not cured, and recent studies have highlighted remarkable genetic heterogeneity in this subset of AML. Here we identify somatic mutations in additional sex combs-like 2 (ASXL2) in 22.7% (25/110) of patients with t(8;21), but not in patients with inv(16)/t(16;16) (0/60) or RUNX1-mutated AML (0/26). ASXL2 mutations were similarly frequent in adults and children t(8;21) and were mutually exclusive with ASXL1 mutations. Although overall survival was similar between ASXL1 and ASXL2 mutant t(8;21) AML patients and their wild-type counterparts, patients with ASXL1 or ASXL2 mutations had a cumulative incidence of relapse of 54.6% and 36.0%, respectively, compared with 25% in ASXL1/2 wild-type counterparts (P = .226). These results identify a high-frequency mutation in t(8;21) AML and identify the need for future studies to investigate the clinical and biological relevance of ASXL2 mutations in this unique subset of AML.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proteínas Represoras / Leucemia Mieloide Aguda / Proteínas de Fusión Oncogénica / Subunidad alfa 2 del Factor de Unión al Sitio Principal / Mutación Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Año: 2014 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proteínas Represoras / Leucemia Mieloide Aguda / Proteínas de Fusión Oncogénica / Subunidad alfa 2 del Factor de Unión al Sitio Principal / Mutación Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Año: 2014 Tipo del documento: Article